Edesa Biotech, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $EDSA in the last 30 days.
See all $EDSA insider activity →Summit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.
Edesa Biotech (EDSA) agreed with Guggenheim Securities to offer 3.87M shares at $5.50 each, plus warrants, and 675K pre-funded warrants at $5.4999, with a 30-day option for 681,825 more. The $23.1M offering, expected to close by Aug 21, 2026, will fund corporate and R&D needs, according to the company.
Edesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 Edesa Biotech Announces Proposed Public Offering TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammat
Over the past 7 days, alphai's AI scored 1 news story mentioning EDSA (Edesa Biotech, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent EDSA coverage spans corporate actions, market movers and earnings.
Capital raise provides funding runway, likely supportive for price.
The raise provides cash for R&D and working capital, likely supporting short‑term liquidity but diluting existing shareholders.
The capital raise provides funding but dilutes existing shareholders; short‑term price impact may be modestly negative.
The capital raise provides immediate financing and dilutes existing shareholders, potentially supporting upcoming clinical milestones.
The dilutive financing overhang is likely to pressure EDSA near-term, with volatility around offering pricing and warrant terms.
alphai scores every news story that mentions EDSA with an AI model for sentiment and relevance, and aggregates insider trades from Edesa Biotech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Summit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.
3 min readEdesa Biotech (EDSA) agreed with Guggenheim Securities to offer 3.87M shares at $5.50 each, plus warrants, and 675K pre-funded warrants at $5.4999, with a 30-day option for 681,825 more. The $23.1M offering, expected to close by Aug 21, 2026, will fund corporate and R&D needs, according to the company.
1 min readEdesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EXHIBIT 99.1 Edesa Biotech Announces Proposed Public Offering TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammat
2 min readEdesa Biotech (EDSA) priced a $25M public offering, including 3.87M common shares, warrants, and pre-funded warrants. The combined offering price is $5.50 per share and warrant. Guggenheim Securities leads the underwriting. The offering is expected to close on August 21, 2026.
1 min readEdesa Biotech (NASDAQ:EDSA) shares dropped 15.2% after hours Wednesday after launching a public offering of common shares and warrants. The company plans to use proceeds for corporate purposes, including R&D and manufacturing. The offering is subject to market conditions and has no guaranteed completion.
3 min readTenon Medical (TNON) shares rose 80% after-hours with no specific news, reporting Q2 revenue of $1.3M (up 127% YoY) and a net loss of $4.1M. BioVie (BIVI) gained 55% after positive Phase 2 trial results for its Parkinson's drug. Edesa Biotech (EDSA) advanced 7% after announcing Phase 2 trial preparations for vitiligo treatment. TransCode (RNAZ) and HCW Biologics (HCWB) also saw after-hours gains on trial updates.
6 min readEdesa Biotech (Nasdaq:EDSA) reported fiscal Q3 2026 results for the three and nine months ended June 30, 2026. It completed Phase 2 preparations for EB06 in moderate-to-severe nonsegmental vitiligo and began activating sites, expecting recruitment in Canada. In ARDS with AKI, paridiprubart plus standard of care showed mortality reductions. Q3 net loss was $5.4M ($0.60/share); cash was $10.3M.
6 min readEdesa Biotech, Inc. (EDSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today rep
6 min readEdesa Biotech (Nasdaq:EDSA) reported fiscal Q3 2026 results for the three and nine months ended June 30, 2026. The company said it completed Phase 2 EB06 vitiligo trial preparations and began activating first investigational sites, with Canada recruitment expected in coming weeks pending approvals. It also reported exploratory paridiprubart ARDS+AKI analyses showing mortality reductions and improved MAKE30. Q3 operating expenses were $5.5M and net loss $5.4M; cash was $10.3M.
7 min readBoundless Bio (BOLD) agreed to an all-stock merger with private Serapha Bio; it expects a pre-close cash dividend and plans to trade as Serapha on Nasdaq under “AATD” in Q4 2026. Monopar (MNPR) said its ALXN1840 Wilson disease NDA is on track for mid-2026. Galectin (GALT) reached FDA agreement on key Phase 3 MASH protocol elements; final protocol due Q3 2026.
7 min read
